Table 1. GALNT2 expression and the clinicopathologic and biologic characteristics of neuroblastoma.
| Variable | Cases | Positive GALNT2expression (%) | P value* |
|---|---|---|---|
| Age at diagnosis | |||
| ≤ 1.5 year | 35 | 23 (65.7) | 0.013 |
| > 1.5 year | 74 | 29 (39.2) | |
| Sex | |||
| Male | 65 | 29 (44.6) | 0.432 |
| Female | 44 | 23 (52.2) | |
| Clinical stage | |||
| 1, 2, and 4S | 32 | 21 (65.6) | 0.016 |
| 3 and 4 | 77 | 31 (40.3) | |
| Primary tumor site | |||
| Adrenal | 67 | 26 (38.8) | 0.019 |
| Extra-adrenal | 42 | 26 (61.9) | |
| INPC histology | |||
| Unfavorable | 50 | 15 (30.0) | 0.001 |
| Favorable | 59 | 37 (62.7) | |
| MYCN | |||
| Amplified | 25 | 7 (28.0) | 0.025 |
| Non-Amplified | 84 | 45 (53.6) |
Abbreviation: INPC, International Neuroblastoma Pathology Classification.
*
χ2 test.